Nanotechnology Now

Our NanoNews Digest Sponsors







Heifer International

Wikipedia Affiliate Button


Home > Press > Correlogic Systems and JEOL Sign Research and Development Agreement

Abstract:
Joint Efforts to Advance Clinical Application of Mass Spectrometry

Correlogic Systems and JEOL Sign Research and Development Agreement

ROCKVILLE, MD | Posted on June 6th, 2007

Correlogic Systems, Inc. and JEOL, Ltd. today announced the signing of a research and development
agreement focused on further enhancing the performance of mass spectrometry
in a clinical setting. JEOL, headquartered in Tokyo, is a leading global
manufacturer of scientific instruments used for research and development in
the fields of nanotechnology, life sciences, optical communication,
forensics, and biotechnology. Correlogic, based in Rockville, Maryland has
pioneered the use of pattern recognition technologies for the development
of proteomic, metabolomic, and genomic based clinical prognostic and
clinical diagnostic tests. Correlogic and JEOL have collaborated for more
than a year under an informal agreement, and have made great strides in the
continuing validation of various mass spectrometer-based assays. Details of
the agreement were not released.

Over the past year, we have had a very close and productive research
collaboration with JEOL," said Peter J. Levine, President and CEO of
Correlogic Systems, Inc. "This agreement formalizes our link to one of the
world's leading mass spectrometer and NMR manufacturers."

####

About Correlogic Systems, Inc.
Correlogic Systems, Inc. has developed patented technology and processes with a wide variety of applications for biomarker discovery, disease detection, and new drug discovery. The technology's first application has been in the field of proteomics -- the study of human proteins. OvaCheck(R), a blood test for the early detection of ovarian cancer, is Correlogic's first diagnostic test using its patented "Hidden Patterns" approach. The test is undergoing the final stages of its extensive validation process. Correlogic has entered into marketing
agreements with Quest Diagnostics, Inc., and Laboratory Corporation of America for North America. Mitsui & Co., Ltd. and Quest Diagnostics are equity investors in Correlogic. Visit Correlogic at http://www.correlogic.com .

About JEOL, Ltd. JEOL is a world leader in electron optical equipment
and instrumentation for high-end scientific and industrial research and
development. Core product groups include electron microscopes (SEMs and
TEMs), instruments for the semiconductor industry (electron beam
lithography and a series of defect review and inspection tools), and
analytical instruments including mass spectrometers, NMRs and ESRs.
Headquartered in Tokyo, Japan, the company has offices throughout the
world.

Cautionary Statement: Certain statements contained in this release are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances. Actual results could differ materially due to, among other
things, operational and other difficulties associated with integrating
acquired business, general business conditions, competition among managed
care companies, rising health costs, trends in medical loss ratios, health
care reform, delay in receipt of regulatory and other approvals for pending
transactions and other regulatory issues.

For more information, please click here

Contacts:
Annette Fribourg
VP Government & Public Relations

301/795-1707

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013

Polymer-coated catalyst protects "artificial leaf" June 17th, 2013

Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013

AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013

Tools

Hitachi announces the SU8200 – a new type of cold field emitter SEM June 17th, 2013

Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013

Closer to reality June 14th, 2013

Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013

Alliances/Partnerships/Distributorships

SEMATECH to Address Critical Supply Chain Challenges and Present Latest Technology Advances at SEMICON West 2013 June 17th, 2013

SEMATECH Names William R. Rozich Chairman of the Board June 13th, 2013

Applied Seals North America Partners with SEMATECH to Improve Semiconductor Manufacturing Sealing Solutions for Vacuum Processing Tools June 12th, 2013

Top quality Cu diffusion barriers from Picosun in the ENIAC JU project ESiP June 10th, 2013

Research partnerships

Nano-thermometer enables first atomic-scale heat transfer measurements June 13th, 2013

New quantum dot technique combines best of optical and electron microscopy June 12th, 2013

2-D electronics take a step forward: Rice, Oak Ridge labs make semiconducting films for atom-thick circuits June 10th, 2013

World's first large(wafer)-scale production of III-V semiconductor nanowire June 10th, 2013

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project








abbigliamento uomo
Computer Accessories
© Copyright 1999-2013 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE